Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
Oslo University Hospital is part of the PERCATHE (Personalised cancer therapies) consortium, aiming to develop new, powerful and frontiers-breaking methods to build an innovative and practicable pipeline for individualised precision treatment of cancer. PERCATHE is one of 14 convergence environments under UiO:Life Science - the largest priority area at UiO. Consortium members - OUS and UIO scientists Arnoldo Frigessi, Olav Engebråten, Vessela Kristensen, Alvaro Köhn Luque and Carl Henrik Gørbitz - have recently published a feature article in the popular science "Knowledge" (Viten) section of the Norwegian major newspaper Aftenposten, entitled "Can statistics and mathematics save as many lives as new medicines?"
A recent study from the Sections of Core Facilities/Radiation Biology/Tumor Immunology shows that the cell cycle can be completely resolved by mass cytometry, including subdivision of the G1 and G2 phases. Only a few markers are needed, and the remaining >50 parameters are free to measure the expression of other (phospho)proteins of interest. Stratification of cells into different cell cycle phases also made exclusion of non-single cell events possible, solving another problem in mass cytometry.
The Genetics and Genomics of Cancer meeting takes place at Holmenkollen Scandic Hotel January 27-28 2020. The meeting is organized by Oslo University Hospital, Faculty of Medicine at UiO, Akershus University Hospital, Vestre Viken Hospital Trust and National Breast Cancer Network. More than 20 international speakers are confirmed.
From major journals, first or last author from the Institute for Cancer Research
Pulido R, Aurtenetxe O, Zaldumbide L, Erramuzpe A, López R, López JI, Cortés JM, Nunes-Xavier CE(2017) Neuroblastoma PTPome analysis unveils association of DUSP5 and PTPN1 expression with poor prognosis Ann Oncol, 28 Suppl 7, vii21 DOI 10.1093/annonc/mdx511.023, PubMed 31952731
Nunes-Xavier C, Flem-Karlsen K, Tekle C, Fodstad Ø(2017) Immunoregulatory Protein B7-H3 Promotes Growth and Decreases Tumor Cell Sensitivity to Anti-Cancer Agents Ann Oncol, 28 Suppl 7, vii12 DOI 10.1093/annonc/mdx509.001, PubMed 31952702
Szwed M, Torgersen ML, Kumari RV, Yadava SK, Pust S, Iversen TG, Skotland T, Giri J, Sandvig K(2020) Biological response and cytotoxicity induced by lipid nanocapsules J Nanobiotechnology, 18(1), 5 DOI 10.1186/s12951-019-0567-y, PubMed 31907052
Goleva-Fjellet S, Bjurholt AM, Kure EH, Larsen IK, Støren Ø, Sæbø M(2020) Distribution of allele frequencies for genes associated with physical activity and/or physical capacity in a homogenous Norwegian cohort- a cross-sectional study BMC Genet, 21(1), 8 DOI 10.1186/s12863-020-0813-1, PubMed 31973699
Jakobi AJ, Huber ST, Mortensen SA, Schultz SW, Palara A, Kuhm T, Shrestha BK, Lamark T, Hagen WJH, Wilmanns M, Johansen T, Brech A, Sachse C(2020) Structural basis of p62/SQSTM1 helical filaments and their role in cellular cargo uptake Nat Commun, 11(1), 440 DOI 10.1038/s41467-020-14343-8, PubMed 31974402